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105
Flecainide has demonstrated unsurpassed antiar-
rhythmic activity in patients with stable ventricular ar-
rhythmias, but its effects in those with ventricular tachy-
cardia or fibrillation have not been evaluated.
Electrophysiologic and hospital evaluation of oral fle-
cainide therapy (150 to 200 mg every 12 hours for 4 to
6 days) was performed in 15 patients with clinically doc-
umented ventricular tachyarrhythmias treated unsuc-
cessfully with an average of 3.7 (range 1 to 10) antiar-
rhythmic drugs. Plasma flecainide concentrations
averaged 769 nglml (range 377 to 1,152). Cardiac con-
duction times increased; AH interval changed by + 29%,
HV interval by +42 %, PR interval by +25 %, QRS
duration by + 14% (all p < 0.01). Ventricular refractory
period increased by 10% (p < 0.01) and corrected sinus
node recovery time lengthened by 153 ms (p < 0.02).
During baseline programmed stimulation, sustained
ventricular tachycardia was induced in six patients and
nonsustained tachycardia (from 6 beats to 30 seconds'
duration) in nine patients using up to three premature
There is a great need for more effective therapy in patients
with malignant ventricular tachyarrhythmias. Flecainide
acetate is a new antiarrhythmic drug that has shown unusual
efficacy in suppressing chronic stable ventricular arrhyth-
mias in oral dosing trials in patients (1-4). Trials of fle-
cainide in the United States (1-3) have shown suppression
of ventricularectopic activity averaging 97% in 32 patients
receiving an average daily dose of 400 mg. In a German
study (4), oral flecainide (200 to 400 mg/day) reduced ec-
topic frequency by over 90% in 20 of 22 patients. These
studies followed promising earlier results in animals and
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ventricular stimuli. Flecainide prevented tachycardia in-
duction in 9 (60%) of 15 patients and improved response
(marked increase in cycle length or difficulty of indue-
tion) in 2 (13%) of 15, for a 73% overall response. Cycle
length of induced rhythms increased by 141 ms after
drug administration in those with inducible responses.
Antiarrhythmic response rate was higher in patients
without coronary artery disease.
Outpatient experience in 10 patients has been gen-
erally concordant with in-hospital evaluation at a median
of 6.5 months. Flecainide has been well tolerated. Un-
expected arrhythmias have included exercise-initiated
tachycardia in one patient and slow, hemodynamically
stable tachycardia (110 beats/min) in another patient.
Oral flecainideis an important antiarrhythmic agent for
the management of inducible ventricular tachyarrhyth-
mias. Cardiac conduction times and ventricular refrac-
toriness increase; favorable responses to programmed
stimulation are frequent and generally predict outpatient
safety and efficacy.
single-dose intravenous trials in patients (5-9). However,
electrophysiologic and antiarrhythmic effects of oral fle-
cainide have not been evaluated in patients with ventricular
tachycardia or fibrillation .
Flecainide possesses favorable pharmacokinetic and
hemodynamic properties (1-3). Sustained antiarrhythmic
action corresponds with a plasma half-life of 20 hours in
patients. Antiarrhythmic activity is present at low plasma
drug concentrations (400 to 800 ng/ml) and confounding
active metabolites have not been identified. Oral flecainide
does not affect heart rate, blood pressure or echocardio-
graphic cardiac function in patients in stable condition.
Modest increases in electrocardiographic PR and QRS in-
tervals occur with little independent effect on QT interval.
Flecainide is also well tolerated, causing occasional but
minor dose-related neurologic manifestations.
Preclinical electrophysiologic evaluations of flecainide
suggest a class I mechanism of action (10-12). Electro-
physiologiceffects of single dose. intravenous flecainide in
0735-1097/83/$3.00
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Electrophysiologic study. Standard electrophysiologic
testing was performed in a manner similar to that described
in previous reports (17,18) . A Bloom programmable stim-
ulator (model DTU 110) was coupled with a multichannel
Irex strip chart recorder. Two quadripolar (6 French) stim-
ulating-recording cardiac electrocatheters were used, one
placed in the high lateral right atrium (later ventricle) and
one across the tricuspid valve . Surface electrocardiographic
leads I, II and V I were recorded simultaneously with atrial
and His bundle electrograms . On placement of the intra-
cardiac electrodes, a complete electrophysiologic study was
performed consisting of the following measurements (19):
I) heart rate, 2) blood pressure, 3) conduction intervals (PQ,
Q!tS, QT, PA, AH, HV), 4) sinus node recovery time,S)
Wenckebach cycle length, and 6) atrial, AV node, His-
Purkinje and right ventricular refractory periods. The atrial
and ventricular paced stimuli were pulsed square wave po-
tentials of 2 ms duration and of amplitudes equal to two to
three times the diastolic threshold .
Programmed ventricular stimulation. After standard
electrophysiologic testing, programmed electrical stimula-
tion was performed at two or three right ventricular sites .
During ventricular pacing, single and double premature stimuli
were introduced after eight paced beats as coupling intervals
decreased progressively by 10 to 20 ms until ventricular
refractoriness was reached. At least two pacing cycle lengths
were used (between 460 and 600 ms). Rapid ventricular
pacing bursts (eight cycles to 200 beats/min) were intro-
duced. Triple premature stimulation was applied in five
patients in whom induction of ventricular tachycardia was
not achieved with double stimuli . Rapid ventricular pacing
was required to terminate induced tachycardia in four pa-
tients and electrical cardioversion was required in one. Non-
sustained ventricular tachycardia was defined as nondriven
patients have also been presented in abbreviated reports (13-
16), but drug actions after multiple dose oral therapy have
not been reported.
Despite the highly favorable response to flecainide in
stable patients , response may differ in patients with malig-
nant ventricular arrhythmias, including ventricular tachy-
cardia and fibrillation. This investigation was designed to
study the effects of multiple oral doses of flecainide on
electrophysiologic measurements and on inducibility ofven-
tricular tachycardia during programmed electrical stimula-
tion in patients with previously documented ventricular
tachyarrhythmia.
Methods
Selection of patients. Fifteen hospitalized patients who
were previously scheduled to undergo electrophysiologic
evaluation and had a clinical history of documented ven-
tricular tachycardia or fibrillation or syncope of presumed
arrhythmic origin were selected for study. All antiar-
rhythmic agents were stopped for at least four serum half-
lives before the study (48 hours for propranolol). Institu-
tional and individual written consent was obtained. Exclu-
sion criteria included second degree or greater atrioventric-
ular (AV) heart block, New York Heart Association functional
class III or IV despite therapy, unstable angina, myocardial
infarction less than 30 days before entry to study, digitalis-
induced arrhythmias and uncorrected hypotension or hy-
pertension. Electrophysiologic inducibility of ventricular
tachycardia was required before initiating drug therapy (see
later). A medically effective means of birth control was
required in female candidates.
Patient characteristics. The study group included 14
men and I woman with an average age of 58.7 years (range
32 to 72). Clinically significant coronary artery disease was
present in nine patients, eight with clinical and electrocar-
diographic evidence for prior myocardial infarction, and one
with confirmation of coronary artery disease at cardiac cath-
eterization. In the other six patients , significant organic heart
disease except for arrhythmia was not manifest. Recurrent
sustained ventricular tachycardia had been documented in
9 of the 15 patients; 3 had experienced ventricular fibrillation
unassociated with acute myocardial infarction, and the other
3 had experienced syncope and were noted to have non-
sustained ventricular tachycardia during monitored evalu-
ation . Conduction system disease was present in four pa-
tients, including atrial fibrillation (one patient) , bradycardia-
tachycardia syndrome treated with an escape ventricular
pacemaker (one patient) and intraventricular conduction de-
lay with a QRS duration of 120 ms or more (two patients).
Before the study, patients had been treated with an average
of 3.7 other antiarrhythmic drugs (range 1 to 10) with an
inadequate antiarrhythmic response or drug intolerance (Ta-
ble I) .
Table 1. Previous Antiarrhythmic Agents
Drug
Amiodarone
Aprindine
Bretylium
Disopyramide
Encainide
Lidocaine
Mexiletine
Phenytoin
Procamamide
Propranolol
Quinidine
Verapamil
Total trials
(15 patients)
PatientsTested
(number)
3
2
3
7
2
7
2
1
12
5
11
I
56
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repetitive responses lasting between 6 beats and 30 seconds.
Sustained ventricular tachycardia was defined as responses
lasting for more than 30 seconds or requiring intervention.
Drug administration and therapeutic evaluation.
Flecainide was administered orally after electrophysiologic
testing at 1600 and 2200 hours and then every 12 hours, with
retesting after 4 to 6 days (mean 4.4). The drug was ad-
ministered in tablet form in doses of 150 mg (patients weigh-
ing less than 50 kg) or 200 mg (supplied by Riker Labo-
ratories, Inc.). Electrophysiologic testing and programmed
ventricular stimulation, using an identical protocol to that
of the control study, were performed during steady state
dosing on flecainide after 4 to 6 days. Blood was obtained
for plasma drug determination just before the second dose
(2145 hours), at the beginning and end of the second drug-
treatment electrophysiologic study (day 4 to 6) and at the
time of any clinical occurrence of tachyarrhythmia. Plasma
concentration of flecainide was measured by gas-liquid chro-
matography as previously described (I). Pre- and post-study
drug concentrations were averaged. Electrocardiographic and
hematologic testing, urinalysis and 20 channel blood bio-
chemistry testing were performed before drug treatment and
on the day of drug retesting. Patients also underwent bicycle
ergometric exercise testing to a symptom-limited end point.
Continuous telemetric monitoring of cardiac rhythm was
performed during hospitalization.
Outpatient follow-up. Patients responding favorably to
in-hospital treatment were continued on outpatient therapy.
Outpatient evaluation was performed at I week, I month,
3 months and at 3 monthly intervals, with 24 hour ambu-
latory electrocardiographic monitoring within 1 month and
at 6-month intervals or as further dictated by clinical
symptoms.
Statistical methods. Results are presented as mean ±
standard deviation. Paired data were analyzed by Student's
t test, with significance taken at a level of 0.05 for two-
tailed hypotheses.
Results
During control electrophysiologic study, nonsustained
ventricular tachycardia was induced in 10 patients and sus-
tained ventricular tachycardia in 5 (Table 2). Multiple dose
drug loading and maintenance therapy were uneventful in
13 patients. In Patient 8, 10 beats of ventricular rhythm
(rate 94 beats/min), occurred after the fourth dose and the
patient was withdrawn from further testing. At the time of
repeat electrophysiologic study during drug treatment, plasma
flecainide concentration averaged 769 ± 215 ng/ml (range
377 to 1,152) (Table 2). This range is similar to that obtained
after short-term dosing in patients with stable arrhythmias
(1-3).
Electrophysiologic Observations
Cardiac conduction intervals (Table 3). Heart rate (cycle
length) and blood pressure were unchanged after flecainide
therapy. A trend favored a mild increase in diastolic blood
pressure (of 5 mm Hg) which did not reach significance.
Moderate increases in PQ (PR) and QRS intervals (aver-
aging 49 and 14 ms, respectively, during sinus rhythm) were
highly significant (p < 0.001). Patients with initial first
degree AV block (PQ > 200 ms) did not manifest a greater
change (+ 46 ms, n = 6). Similarly, those with initial
intraventricular conduction delay (QRS :::=: 100 ms) showed
similar or smaller QRS increases than the group as a whole
( + 11 ms, n = 6). The corrected QT interval (QTc) in-
creased by an average of 27 ms (p < 0.002); when corrected
for heart rate and increases in QRS (JTc) , the average in-
crease of 13 ms did not reach significance.
His conduction intervals increased significantly. PA in-
terval, a measure of intraatrial conduction, increased during
spontaneous (12 ms, p < 0.001) but not paced rhythm. AH
interval, a measure of AV nodal conduction, increased signif-
icantly during spontaneous (17 ms, p = 0.001) and paced
rhythms (p < 0.05). HV interval, a measure of His-Purkinje
conduction, increased by an average of 18 and 22 ms (p :s
0.005) during spontaneous and paced rhythms, respectively.
Patients with an initially prolonged HV interval (:::=:55 ms)
did not experience a greater drug effect (+ 13 ms, n = 3).
In summary, cardiac conduction times generally lengthened
after oral flecainide, the most notable increase being in His-
Purkinje conduction.
Sinus node recovery (Table 2). Corrected sinus node
recovery time was variably affected by flecainide, but the
average change (+ 136 ms) represented a significant in-
crease (p < 0.02). Increases were not of clinical signifi-
cance. The largest increment (from 530 to 980 ms) occurred
in Patient 14 with known sick-sinus syndrome.
AV node Wenckebach conduction. No change oc-
curred in average AV node Wenckebach cycle length. An
increase occurred in 6, a decrease in 4 and essentially no
change in 3 of 13 patients.
Cardiac refractory periods. Mean atrial effective re-
fractory period increased by 12 ms, but this was not sig-
nificant (p > 0.1). Eight patients showed an increase, three
a decrease and two no change in this measurement. No
significant change in AV node effective refractory period
accompanied flecainide treatment. This measurement in-
creased in 6 and decreased in 7 of 13 pairs. Atrial refrac-
toriness occurred before that of the AV node during the
control study in one patient and during the drug study in
six. There was no change in AV node functional refractory
period. This measurement increased in six, decreased in five
and was unchanged or indeterminate in two. In contrast,
right ventricular effective refractory period increased sig-
nificantly, averaging +25 ms (p < 0.01). Increases were
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Table 2. Electrophysiologic Observations: Ind ividual Patient Data
Age (yr)1
Clinical Diagnosis
Cp
Interval (ms)
Case Sex Study Cardiac Rhythm (ng/rnl) CSNRT WCL AERP AVNERP AVNFRP RVERP
621M C CAD VTs 265 500 300 420 490 250
FI 654 240 460 240 390 535 260
2 54/M C CAD VF.AF 260
FI 717 250
3 121M C CAD VTs 365 510 260 450 530 260
FI 696 410 620 280 500 < 540 280
4 621M C CAD VTs 310 380 260 330 410 260
FI 680 360 430 340 350 440 270
5 64/M C ldio Syncope 280 380 260 < 300 < 360 250
( + VTNS)
FI 1081 500 420 350 < 375 440 300
6 52/M C Idio VTs 390 < 400 240 430 440 280
FI 678 340 < 400 260 < 310 430 300
7 62/M C CAD VTs 170 600 310 670 720 280
FI 11 52 440 720 320 700 710 330
8* 74/M C CAD VTs 335 440 260 410 480 240
FI 755
9 321F C ldio Syncope 140 430 270 460 495 260
(+ VT"s)
FI 929 320 440 310 < 380 440 270
10 44/M C Idio Syncope 230 380 260 330 460 240
(+ VTNS)
FI 377 190 540 270 480 540 260
II 321M C Idio VTs 280 480 300 370 585 310
FI 482 370 480 330 < 360 620 300
12 57/M C CAD VF 0 800 320 800 840 270
FI 872 320 520 250 320 640 300
13 71/M C CAD VF 420 560 300 450 540 280
FI 751 770 500 300 430 540 320
14 74/M C Idio;SSS VTs 530 620 300 600 600 220
FI 1049 980 620 300 < 380 580 310
15 68/M C CAD VTs 375 500 340 370 560 300
FI 660 285 560 450 < 460 590 ND
Mean C 289 < 505 286 < 460 < 546 263
±SD ± 136 ± 120 ±30 :!: 147 ± 129 ±22
FI 425 < 516 308 < 418 < 542 288
±220 ± 94 ±55 ± 103 ±87 ±25
p value (C vs F1) < 0.02 > 0.5 > 0.1 > 0.2 > 0.5 <0.01
*Excluded before second study; control data thus not used to calculate means for paired comparison.
AERP = atrial effective refractory period (normal. 170 to 300 ms); AF = atrial fibrillation: AVNERP = AV node effective refractory period
(normal. 230 to 425 ms); AVNFRP = AV nodal functional refractory period (normal. 330 to 525 ms); C = control; CAD = coronary artery disease;
Cp = ftecainide concentration in plasma; CSNRT = corrected sinus node recovery time (normal. < 500 ms) F = female. FI = ftecainide; Idio =
idiopathic (normal function); M = male; RVERP = right ventricular effective refractory period (normal. 170 to 290 ms): SO = standard deviation:
SSS = sick-sinus syndrome; VF = ventricular fibrillation; VTNS = ventricular tachycardia. nonsustained (6 beats to 30 seconds); VTs = ventricular
tachycardia. sustained (>30 seconds); WCL = Wenckebach cycle length
noted in II and decreases in only 2 of 13 paired measure-
ments. In summary, significant effects of f1ecainide on re-
fractory periods were limited to ventricular muscle where
increases averaging 10% were noted .
Programmed ventricular stimulation (Table 4). During
the control study, sustained ventricular tachycardia was in-
duced in six and nonsustained tachycardia in nine patients.
Cycle length of the most sustained induced rhythm averaged
313 ± 88 ms (range 200 to 500). The pattern of the induced
rhythm was discrete in nine patients and polymorphous in
six . Initiation of the most sustained rhythm was accom-
plished by atrial pacing in one patient , single premature
ventricular stimulation (S,Sz ) in three, double premature
stimulation (S,SZS3) in seven, triple premature stimulation
(S,SZS3S4) in three and ventricular burst pacing in one pa-
tient. Induced rhythms terminated spontaneously in 12 pa-
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Table 3. Mean Pressure and Interval Data
Variable
Study
(no. of patients) Control Flecamide p Value
Cycle length (ms)(\ 3)
a) 984 ± 215 953 ± 173 05
b) 600 600
PA interval (ms)(\3)
a) 28 ± 8 40 ± 10 <0.001
b) 49 ± 18* 55 ± 14 >0 2
AH interval (ms)(\2)
a) 118 ± 36 135 ± 26 0.001
b) 175 ± 79 226 ± 81 <0.05
HV interval (ms)(\2)
a) 50 ± II 68 ± 21 0.005
b) 53 ± 13 75 ± 21 <0 005
PQ (PR) interval (ms)(\3)
a) 200 ± 46 249 ± 54 <0.001
b) 279 ± 94t 359 ± 99 <0.01
QRS interval (ms)(\4)
a) 97 ± 18 III ± 19 <0 001
b) 101 ± I7 115 ± 20 <0 001
QT interval (ms)(\4)
a) 385 ± 35 409 ± 34 <0.005
b) 359 ± 30 389 ± 29 <0.005
QTc interval (ms)(\4)
a) 396 ± 41 423 ± 33 <0.002
JTc interval (ms)(\4)
a) 299 ± 39 312 ± 24 0.1
Systolic BP (mm Hg)(14)
a) 127 ± 15 126 ± 16 >0.5
Diastolic BP (mm Hg)(\4)
a) 78 ± 13 83 ± 12 >0.05
Mean BP (mm Hg)(I4)
a) 94.3 ± 12.4 97.4 ± 11.7 >0 2
a) during spontaneous rhythm, b) dunng atrial pacing (cycle length 600
ms); * = stimulus to low atrial (SA) interval; t = stimulus to Q (SQ)
interval.
BP = blood pressure; JTc = QT interval corrected for heart rate and
increases in QRS duration; p = probability.
tients, required rapid ventricular pacing in four (one of whom
also required lidocaine) and required electrical cardioversion
in one.
Flecainide therapy was judged successful by pro-
grammed stimulation in nine patients (60%), partially suc-
cessful in two (13%) (marked reduction in induced ventric-
ular rate to less than 100 beats/min) and was unsuccessful
in four (27%), Rhythms induced in partially successful and
unsuccessful trials included sustained ventricular tachy-
cardia in three, sustained ventricular rhythm in one, non-
sustained ventricular tachycardia in one and nonsustained
ventricular rhythm in one. Termination was spontaneous in
two; rapid ventricular pacing was used for termination in
four, one of whom also required lidocaine.
The cycle length of induced ventricular rhythms was reg-
ularly increased after fiecainide (p < 0.001, Wilcoxon)
(Fig. 1, Table 4). In four patients, 0 to 2 beats at most
could be induced after flecainide. In 11 patients with at least
three beats of induced repetitive rhythm, the average cycle
length increased by 141 ms from 302 ± 96 to 443 ± 110
ms (p < 0.01) (Fig. 1). In six patients with nonsustained
or sustained ventricular tachycardia induced despite fle-
cainide, tachycardia cycle length was also significantly in-
creased from 343 ± 100 to 504 ± 112 ms (p < 0.05).
Cycle length of the longest episode of induced rhythm de-
creased only in Patient 1 (Fig. 1), but the configuration of
this tachycardia differed and the cycle length of the first
configuration increased. In the patient group in which ther-
apy was unsuccessful, ventricular tachycardia was less read-
ily induced in one, similarly induced in four and more read-
ily induced in one patient after flecainide. Termination of
tachycardia in these patients was of similar difficulty in two,
more difficult in two and less difficult in two patients com-
pared with that before flecainide. An example of a successful
electrophysiologic response to flecainide is presented in Fig-
ure 2 (Patient 6).
Outcome at electrophysiologic study was compared with
patient characteristics (20). Three of nine patients with
coronary artery disease versus six of six without coronary
artery disease were successfully treated (p < 0.01). How-
ever, five of nine (56%) with coronary disease showed at
least a partial response (p = not significant [NSD, and
outpatient therapy was begun in four of the five. Three of
six patients with sustained versus six of nine with nonsus-
tained ventricular tachycardia were successfully treated
(p = NS). If partial successes are also considered, four of
six with sustained versus six of eight with nonsustained
ventricular tachycardia induced at the control study re-
sponded favorably (p = NS). Four of six patients with
polymorphous ventricular tachycardia versus five of nine
with discrete ventricular tachycardia were successfully treated
(p = NS). The age of successfully treated patients averaged
53.4 ± 15.4 years (n = 9) compared with 66.7 ± 5.1
years (n = 6) in those partially responsive or unresponsive
(p > O. I). There was no difference in plasma concentration
of flecainide in those responding successfully at electro-
physiologic study (765 ± 241 ng/ml) as compared with
those in whom therapy was partially successful or unsuc-
cessful (775 ± 190 ng/rnl).
Clinical Correlations
In-hospital versus outpatient responses. All patients
underwent exercise testing as part of in-hospital evaluation
before discharge. In Patient 2, bicycle ergometric exercise
induced sustained ventricular tachycardia at submaximal ex-
ercise (rate 160 beats/min) and was associated with hypo-
tension and presyncope before converting spontaneously after
2 minutes. A presyncopal episode unmonitored during a hot
shower 2 days earlier during ftecainide therapy may have
represented an unrecognized episode of ventricular tachy-
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Table 4. Result of Programmed Cardiac Stimulation
Cycle Mode Result
Cp Induced Rhythm Length of
Case Study (ng/ml) (no. of nondriven beats) (ms) Morphology Initiation Termination Therapy
C a) VTs 430 RAD/RBBB A pace Lido;RVP
b) VTNS (10) 325 LAD/RBBB S,S2S,S4 Spont
FI 654 VTs 375 LAD/RBBB S,S2S,S4 Spont;RVP F
2 C VTNS (15) 210 Poly S,S2S,S4 Spont
Fl 717 4 310 Poly S,S2S,S4 S
3 C VTNS (14) 320 LAD/RBBB S,S2S, Spont
Fl 696 0 S,S2S, S
4 C VTs 325 LAD/RBBB S,S2S,S4 Cardioversion
Fl 680 VRs 610 LAD/RBBB S,S2S, Spont,RVP PS
5 C VTNS (6) 220 Poly S,S2S, Spont
Fl 1,081 4 400 RAD/RBBB S,S2S, Spont S
6 C VTs 370 LAD/RBBB S,S2 RVP
FI 678 3 440 LAD/RBBB S,S2S, S
7 C VTNS (13) 270 Poly S,S2S, Spont
Fl 1,152 a) VTNS (12) 500 LAD/RBBB S,S2S, spont~ PS
b) VTs 450 NLlRBBB S,S2S, RVP
8* C VTNS (12) 245 LAD/RBBB S,S2S, Spont
Fl 755 VRNS (10) 640 LAD/RBBB Spont* Spont F
9 C VTNS (20) 200 Poly S,S2 Spont
Fl 929 3 360 Poly S,S2S, S
10 C a) VTNS (13) 395 RAD/LBBB V burst Spont
b) VTs 340 RAD/LBBB V burst; RVP
Isuprel
Fl 377 2 S,S2S,S4 S
V burst
II C VTs 430 NL-LAD/ S,S2S, RVP
LBBB
FI 482 2 S,S2S,S4 S
12 C VTNS (6) 260 Poly S,S2S,S4 Spont
Fl 872 3 340 Poly S,S2S,S4 S
13 C VTNS (6) 290 Poly S,S2S, Spont
FI 751 VTNS (10) 400 LAD/RBBB S,S2S, Spont F
14 C VTNS (17) 280 RAD/RBBB S,S2S, Spont
FI 1,049 0 S,S2S, S
15 C VTs 500 RAD/LBBB S,S2 Spont
Fl 660 VTs 550 LAD/LBBB Catheter Lido;RVP F
(mechanical)
*Dld not undergo repeat programmed stimulation; nonsustamed ventncular tachycardia occurred spontaneously.
A = atrial; F = failure; LAD = left axis deviation; LBBB = left bundle branch block-type configuratIon (lead V,); Lido = lidocaine; NL =
normal; PS = partially successful; Poly = polymorphous, RAD = right axis deviatIon, RBBB = right bundle branch block-type configuration (lead
V!l; RVP = rapid ventricular pacing; S = successful; Spont = spontaneous; V burst = ventricular burst pacmg (~300 ms); VRNS = ventncular
rhythm, nonsustained; VRs = ventricular rhythm, sustained; VTNS = ventricular tachycardia, nonsustamed (6 beats-30 seconds); VTs = ventricular
tachycardia, sustained (>30 seconds).
cardia. On subsequent procainamide therapy, no exercise
ventricular tachycardia could be induced despite electro-
physiologic induction of nonsustained, polymorphous ven-
tricular tachycardia.
Ten other patients showing partial or complete success
at electrophysiologic testing and during in-hospital evalu-
ation were discharged on oral flecainide therapy for out-
patient management and have been followed up for a median
of 6.5 months (range 0.4 to 7.6), In general, inpatient eval-
uation has correlated with outpatient response. Nine patients
have continued on flecainide therapy with control of ven-
tricular arrhythmias predicted by in-hospital evaluation. The
tenth patient (Patient 3) developed slow sustained ventric-
ular tachycardia (rate 110 beats/min) after 2 weeks of out-
patient therapy. Conversion to sinus rhythm was readily
accomplished with a 50 watt/s shock, and alternative therapy
was begun.
Patient 4 has shown infrequent episodes of well tolerated
or asymptomatic isochronic ventricular rhythm on Holter
monitor evaluation, as could be predicted from electro-
physiologic testing. Patient 5 has had no recurrence of syn-
cope; occasional escape ventricular beats have been noted
during sleep monitoring. Patient 6, previously refractory to
10standard and experimental drugs and inadequately treated
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every 12 hours). Patient 11 has noted no episodes of sus-
tained ventricular tachycardia during 6.1 months of treat-
ment. However, amiodarone , discontinued 6 weeks before
testing. has been reinstituted at a low dose after recurrence
of single and nonsustained ventricular ectopic activity at 3
months, suggesting residual amiodarone effect at the time
of initial testing . Patient 12 has had no recurrence of syn-
cope or ventricular tachycardia or fibrillation during 5.9
months of flecainide therapy. A rate-related left bundle branch
block noted during exercise has responded to dosage re-
duction (200 to 150 mg every 12 hours). In Patient 14,
ventricular tachycardia has been prevented during 3.0 months
of outpatient therapy with flecainide, 150 mg every 12 hours .
(Attempt at dosage reduction to 100 mg every 12 hours was
associated with recurrence of single and nonsustained ven-
tricular ectopic activity.)
Side effects. No specific biochemical or clinical adverse
effect s were noted except for the rhythm events just sum-
marized and neurologic manifestation s. Blurring of vision
on lateral gaze with or without lightheadedness or dizziness
was commented on by 10 patient s. Symptoms abated with
dosage reduction in six and were minor in four.
Discussion
There is a manifest need for new antiarrhythmic agent s
that are useful in patient s with malignant ventricular ar-
rhythmias (21,22) . The response to flecainide in our small
group of patients with clinical ventricular tachycardia or
fibrillation is promising and suggests that it may be a useful
therapeutic addition.
Response to ftecainide at programmed stimulation.
Of 15 consecutive patients with qualifying ventricular ar-
rhythmias , II (73%) had a favorable response to provocative
testing; in 9 (60%), respon se at programmed stimulation
was complete , and 9 (60%) continue to benefit from out-
patient flecainide therapy after a median period of 6.5 months.
As expected , response rate is lower in this refractory group
with malignant arrhythmias than in stable patient groups
with isolated ventricular ectopic beats, where about 90%
respond with an average suppre ssion of ventricular arrhyth-
mia of over 95% (1-4 ) .
The response to flecainide as determined electrophysio-
logically appears to compare favorably with that reported
for most standard and experimental drug regimens for ven-
tricular tachycardia at electrophysiologic testing . Standard
class I antiarrh ythmic agents (quinidine , procainamide, di-
sopyramide, lidocaine and phenytoin) and several investi-
gational agents have been reported to be successful in 10
to 45% of patients (23-28). The moderate disparity among
different laboratories is most likely related to differences in
protocol, method of efficacy rating and patient selection bias
(20,29,30). Encainide, another potent investigational agent,
Flecouude
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with an implanted ventricular burst pacemaker, has had no
recurrence of clinical or monitored arrhythmia during 7.3
months of follow-up (Fig. 2). Patient 7 has had approx i-
mately monthly recurrences of slow ventricular tachycardia ,
as predicted electrophysiologically, which have been ter-
minated in each instance by a permanently implanted ven-
tricular pacemaker capable of rapid ventricular burst pacing.
Patient 9 has noted neither syncope nor ventricular ectopic
activity on ambulatory Holter monitor during 6.6 months
of treatment.
Patient 10 , with the lowest plasma level of flecainide
during in-hospital testing, has had no recurrence of syncope
during 6.3 months of treatment; recurrence of lightheaded
episodes and associated nonsustained bursts of ventricular
rhythm were eliminated with dosage increase (to 250 mg
Figure 1. Change in cycle length of ventricular tachycardia (VT)
as a result of flecainide therapy . Patients with 5 or fewer repetitive
beats (therapeutic success) with therapy are indicated with dashed
lines. Patients with nonsustained or sustained ventricular tachy-
cardia are indicated with solid lines . N.I. represents "nonindu-
cible" (=52 beats). Solid bar (Y axis , control) indicates mean of
control cycle lengths. Open bar (Y axis, flecainide) represents
mean of postdrug cycle length in patients with three or more
induced repetitive beats .
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Figure 2. Example of surface (VI) and intra-
cardiac right ventricular (RV) electrograms in
Patient 6, successfully treated with flecainide .
A, Control study showing inductionof sustained
ventriculartachycardiaduring ventricular pacing
(S, ) with single premature ventricular stimulus
(Sz), B. During flecainide therapy. failure of
arrhythmia induction despite double premature
ventricular stimulation (Sz. S3) is observed. Time
intervals on X axis are 0.04 second per small
division.
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has shown a 50 to 60% rate of efficacy in ventricular tachy-
cardia as guided by programmed ventricular stimulation
(31,32) . Direct comparative studies will be required to de-
fine relative efficacies reliably .
Role of programmed stimulation in drug testing. The
role of programmed electrical stimulation as a predictor of
drug efficacy remains somewhat controversial, especially in
patients in whom only nonsustained ventricular tachycardia
is induced (29), Electrophysiologic protocols continue to
evolve , and standardization has not occurred. Thus, drug
response rate depends on the induction protocol and the
patient population as well as the drug itself (20, 30). The
addition of a third extrastimulu s to the Stanford University
protocol , for example, was associated with a decrease in
overall success rate, defined electrophysiologically , from
71 to 32% for multiple drug trials (30). However, the clinical
predictive value of successful testing was not improved and
may have diminished with the more aggressive testing (30,33).
Similarly, the definition of a successful end point has been
debated . Our view has been to use at least two premature
ventricular stimuli during drug testing and to add a third
extrastimulus if this was required to induce the clinical ar-
rhythmia during the control study . Our definition of over
five repetitive beats to separate a successful from an un-
successful response is based on experience from several
laboratories (26,27,33,34). Early clinical correlations (see
later) appear favorable.
Mason et al. (20) identified five clinical predictors of
drug efficacy or inefficacy . Favorable patient characteristics
included: no coronary disease , female sex , no structural
heart disease with good ventricular function and youth . Inef-
ficacy at drug testing using an electrophysiologic guide was
higher in patients with multiple vessel coronary artery dis-
ease, left ventricular aneurysm, long standing arrhythmia
with multiple drug failures and frequent arrhythmia rec-
currence. Although our study is too small to allow evalu-
ations of all these factors when applied to f1ecainide, it is
of some interest that a better response rate was noted in
those without coronary artery disease . Successfully treated
patients also tended to be younger . Monomorphic ventric-
ular tachycardia associated with an otherwise normal elec-
trocardiogram (Patient 10) was also f1ecainide responsive
(35). Thus , it appears likely that certain clinical predictors
associated with response of ventricular tachycardia to other
drugs will apply to f1ecainide.
Comparative electrophysiologic effects. Electroph ysi-
ologic effects of multiple dose, orally administered antiar-
rhythmic drug therapy may not be identical to those of
single dose intravenous therapy. Whereas the potent inves-
tigational antiarrhythmic agent, encainide depresses con-
duction at all levels (atrium . AV node, His-Purkinje system ,
ventricle and accessory pathway) and increases refractory
periods of atrium, ventricle and accessory pathway when
administered orally, it has no significant effects on AV node
conduction or atrial or ventricular refractoriness when ad-
ministered intravenously (36). These differences may relate
to the presence of slowly accumulating active metabolites .
Multiple dose oral f1ecainide resulted in significant slow-
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ing in cardiac conduction at all levels, but increases in
refractory period were limited to the ventricle. In contrast
to the disparate findings with encainide, electrophysiologic
effects after multiple dose oral flecainide are similar to those
after single dose intravenous drug (I to 2 mm/kg) (13-16).
Hellestrand et al, (15) noted a 14% increase in PA interval
and a 19% increase in AB interval compared with 12 and
29% increases (paced rhythm) in our study. Increases in
HV interval have been a consistent finding after intravenous
drug administration ranging from 28 to 46% compared with
42% in our study (13-16). Olsson and Edvardsson (16)
noted a 19% increase in PQ (PR) interval compared with
the 25% increase in our study. Small increases in QRS
interval have been consistently noted after intravenous drug
administration, with a range of II to 19% (l3-l6); an in-
crease of 14% was observed in our study after oral dosing.
A consistent increase in ventricular refractory period, av-
eraging approximately 10%, occurs both after intravenous
drug (16) and oral therapy (present study). Increases in QT
interval and atrial and AV node effective refractory periods
of 5 to 10% (of variable significance) occur after admin-
istration of drug by both routes. The potential for variable
increases in sinus node recovery time, observed in our study,
was also commented on by Seipel et al. (14). Exaggerated
responses in patients with sick-sinus syndrome were recently
reported by Vik-Mo et al. (37). Electrophysiologic effects
of flecainide in the canine heart are similar (12).
In summary, increases in cardiac conduction time of 15
to 35% occur after therapeutic dosing with both oral and
intravenous drugs and are associated with an approximate
10% increase in ventricular refractory period. These findings
are consistent with evidence that the parent drug rather than
active metabolite is responsible for flecainide' s electro-
physiologic actions. Electrophysiologic effects of flecainide
also appear to be generally similar in magnitude to those of
oral encainide, except possibly for the atrial effective re-
fractory period (36).
Specific observations on clinical response. In general,
we found that inpatient evaluation predicted outpatient re-
sponse. With the exception of Patient 3, rhythms evoked
by electrophysiologic and exercise testing and in-hospital
monitoring were predictive of those found clinically during
outpatient observations in those continued on flecainide ther-
apy. As noted by other authors (20-26), programmed elec-
trical stimulation appears to provide a useful means of eval-
uation of antiarrhythmic response in patients without frequent
ambulatory arrhythmias but with a history of ventricular
tachycardia or fibrillation. The induction of ventricular
tacyhcardia with exercise, noted in Patient 2, has also been
reported with encainide and other potent antiarrhythmic agents
(32,38-40). Thus, exercise testing during flecainide therapy
may be indicated, irrespective of results of electrophysio-
logic testing at rest. Flecainide regularly reduces the rate of
ventricular tachycardia, regardless of overall outcome. The
induction requirement in patients who fail to respond to the
drug may be either more or less demanding and the duration
of induced ventricular tachycardia either more or less
sustained.
Proarrhythmic responses may occur in association with
a wide range of antiarrhythmic drugs (39,40). Winkle et
al. (38) noted the risk of encainide-induced ventricular tach-
yarrhythmias to be II % in 90 patients with a history of
ventricular tachycardia or fibrillation. A larger number and
wider spectrum of patients with arrhythmias will be required
to assess this adverse potential for flecainide. In our series,
proarrhythmic potential did not appear excessive, In-hos-
pital, comprehensive evaluation during initial oral dosing
with flecainide, including electrophysiologic testing where
appropriate, appears to be an effective way of selecting
patients with malignant arrhythmias suitable for long-term
therapy. This study should encourage further use of fle-
cainide in controlled settings in patients with serious ven-
tricular arrhythmias.
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